{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T02:00:22Z","timestamp":1762480822928,"version":"build-2065373602"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,26]],"date-time":"2020-04-26T00:00:00Z","timestamp":1587859200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.gore.2020.100577","type":"journal-article","created":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T22:14:08Z","timestamp":1588284848000},"page":"100577","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["An application of ERBB2 receptor inhibitors in a rare case of S310F somatic ERBB2 mutation of primary signet-ring cell adenocarcinoma of vagina: A case report and review literature of S310F somatic ERBB2 mutation in breast and gynecologic cancers"],"prefix":"10.1016","volume":"32","author":[{"given":"June Y.","family":"Hou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason D.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vuthinun","family":"Achariyapota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gore.2020.100577_b0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1477-7819-10-7","article-title":"A new case of primary signet-ring cell carcinoma of the cervix with prominent endometrial and myometrial involvement: Immunohistochemical and molecular studies and review of the literature","volume":"10","author":"Giordano","year":"2012","journal-title":"World J Surg Oncol."},{"key":"10.1016\/j.gore.2020.100577_b0010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.gore.2016.01.004","article-title":"Primary signet ring cell adenocarcinoma of the uterine cervix - A rare neoplasm that raises the question of metastasis to the cervix","volume":"16","author":"Cracchiolo","year":"2016","journal-title":"Gynecol Oncol Rep."},{"issue":"3","key":"10.1016\/j.gore.2020.100577_b0015","doi-asserted-by":"crossref","first-page":"514","DOI":"10.4103\/0973-1482.119366","article-title":"Rare case of primary mucinous adenocarcinoma of vagina","volume":"9","author":"Dhorepatil","year":"2013","journal-title":"J Cancer Res Ther."},{"issue":"40","key":"10.1016\/j.gore.2020.100577_b0020","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.3748\/wjg.v21.i40.11428","article-title":"Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge","volume":"21","author":"Pernot","year":"2015","journal-title":"World J Gastroenterol."},{"issue":"4","key":"10.1016\/j.gore.2020.100577_b0025","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.bbrc.2014.07.025","article-title":"Mechanisms behind signet ring cell carcinoma formation","volume":"450","author":"Fukui","year":"2014","journal-title":"Biochem Biophys Res Commun."},{"key":"10.1016\/j.gore.2020.100577_b0030","unstructured":"COSMIC. Catalogue of Somatic Mutations in Cancer [cited 2018 February 11]. Available from: http:\/\/cancer.sanger.ac.uk\/cosmic."},{"issue":"D1","key":"10.1016\/j.gore.2020.100577_b0035","doi-asserted-by":"crossref","first-page":"D777","DOI":"10.1093\/nar\/gkw1121","article-title":"COSMIC: somatic cancer genetics at high-resolution","volume":"45","author":"Forbes","year":"2017","journal-title":"Nucleic Acids Res."},{"issue":"7517","key":"10.1016\/j.gore.2020.100577_b0040","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","author":"Cancer Genome Atlas Research N","year":"2014","journal-title":"Nature."},{"issue":"1","key":"10.1016\/j.gore.2020.100577_b0045","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/j.clbc.2016.08.001","article-title":"A Rare Case of S310F Somatic ERBB2 Mutation in a HER2-Nonamplified Breast Cancer","volume":"17","author":"Jasra","year":"2017","journal-title":"Clin Breast Cancer."},{"issue":"9","key":"10.1016\/j.gore.2020.100577_b0050","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.6004\/jnccn.2015.0132","article-title":"Prolonged Response to Trastuzumab in a Patient With HER2-Nonamplified Breast Cancer With Elevated HER2 Dimerization Harboring an ERBB2 S310F Mutation","volume":"13","author":"Chumsri","year":"2015","journal-title":"J Natl Compr Canc Netw."},{"issue":"36","key":"10.1016\/j.gore.2020.100577_b0055","doi-asserted-by":"crossref","first-page":"14476","DOI":"10.1073\/pnas.1203201109","article-title":"Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2","volume":"109","author":"Greulich","year":"2012","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"9","key":"10.1016\/j.gore.2020.100577_b0060","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1634\/theoncologist.2014-0054","article-title":"Treatment of metastatic extramammary Paget\u2019s disease associated with adnexal adenocarcinoma, with anti-HER2 drugs based on genomic alteration ERBB2 S310F","volume":"19","author":"Vornicova","year":"2014","journal-title":"Oncologist."},{"issue":"25","key":"10.1016\/j.gore.2020.100577_b0065","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1200\/JCO.2013.49.0599","article-title":"Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapy","volume":"32","author":"Ali","year":"2014","journal-title":"J Clin Oncol."},{"issue":"22","key":"10.1016\/j.gore.2020.100577_bib76","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1200\/JCO.2009.26.9571","article-title":"Phase II, Open-Label Study of Pazopanib or Lapatinib Monotherapy Compared With Pazopanib Plus Lapatinib Combination Therapy in Patients With Advanced and Recurrent Cervical Cancer","volume":"28","author":"Monk","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.gore.2020.100577_b0070","first-page":"396","article-title":"The prognostic value of HER-2\/neu oncogene in cervical cancer","volume":"27","author":"Ndubisi","year":"1997","journal-title":"Ann Clin Lab Sci."}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578920300436?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578920300436?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T01:55:31Z","timestamp":1762480531000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578920300436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":15,"alternative-id":["S2352578920300436"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2020.100577","relation":{},"ISSN":["2352-5789"],"issn-type":[{"type":"print","value":"2352-5789"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An application of ERBB2 receptor inhibitors in a rare case of S310F somatic ERBB2 mutation of primary signet-ring cell adenocarcinoma of vagina: A case report and review literature of S310F somatic ERBB2 mutation in breast and gynecologic cancers","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2020.100577","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100577"}}